未設定

USA healthcare information – ASTHO event on YouTube and analytics

ASTHO **** EVENTDate: Monday, November 22 Time: 12:00 PM – 1:00 PM ET Please click the following link during the event to attend. White House Virtual Event: Public Health Community Appreciation Town Hall – YouTube A recording will also be available at this link after the event. ASTHO BLOG STAT Episode 187: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving Here’s more on…

FDA Authorizes Pfizer-BioNTech COVID-19, but delays Moderna

Pfizer vaccine for kids earns a perfect score from CDC panel Pfizer-BioNTech’s COVID-19 vaccine was authorized for use in children as young as 5 years old, for which was the first emergency use authorization(EUA) in the U.S. The existing EUA to include children ages 5 to 11 after the vaccine produced an immune response that was comparable to the response seen in people ages 16 to 25, and showed…

Inside the vaccine race, how a Covid pill failed, & Biogen’s troubled launch

STAT : Episode 182 Here’s the latest on the FDA commissioner; here’s STAT’s coverage of the booster debate; here’s the news on genome editing; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic. STAT: Episode 183 Here’s where you can pre-order Zuckerman’s book; here’s the news from Atea Pharmaceuticals; here’s the latest on…

Public Health Federal Government Remains Open, FMAP Extended for Territories Oct. 1, 2021

Public Health Analysis Last night, Congress approved and the President signed the Extending Government Funding and Delivering Emergency Assistance Act (HR 5305), a continuing resolution (CR) to fund the federal government through Dec. 3, 2021. The bill does not include a provision to increase the debt ceiling as an earlier version did. Congress will have to address this provision separately…

56: Prevention for the Next Generation – Addressing Adverse Childhood Experiences, Suicide, and Overdose and Public Health Analysis in USA

Public Health Analysis Last night, the House of Representatives passed the Extending Government Funding and Delivering Emergency Assistance Act (H.R. 5305) – also known as a continuing resolution (C.R.). If approved by the Senate and signed into law, this bill would extend funding for the federal government through Dec. 3, 2021, and raise the debt ceiling through Dec. 16, 2022. The C.R. also…

Biden’s drug pricing plan, Wall Street’s Alzheimer’s fixation, & daily 5 a.m. alarms

Can drug pricing help Democrats keep the Senate? Why is there still no nominee for FDA commissioner? And when will we get snortable vaccines? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT Washington correspondent Nicholas Florko joins us to explain President Biden’s proposal to lower drug prices, how it might affect the 2022 election, and why…

The mRNA gold rush, Delta’s alarming rise, & the next treatment for Alzheimer’s

Who’s going to win the mRNA bake-off? How worrisome is the Delta variant? And why do drug names sound like Raffi lyrics? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we dive into the potential of mRNA, a technology that proved itself with Covid-19 vaccines and is now seeding a pharmaceutical gold rush. Then, STAT’s Helen Branswell joins us to discuss…

The quest for a Covid pill, a microbiome gut-check, & CRISPR on the big screen

How long do vaccines last? Is the microbiome overhyped? And who should play Jennifer Doudna in a movie? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss the CDC’s about-face on mask wearing, the debate over vaccine booster shots, and the slow but steady race to develop pills for Covid-19. Then, STAT’s Kate Sheridan joins us to discuss a setback…

Breakthrough infections, the power of lobbying, & pharma’s cinematic villainy

Did we take off our masks too soon? Can Democrats pass a drug pricing bill? And do pharma CEOs get weapons training? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, Céline Gounder of NYU’s Grossman School of Medicine joins us to discuss the issue of breakthrough coronavirus infections and whether the U.S. was too quick to unmask. Then, STAT’s Rachel…

The FDA’s future, Biden’s tight ship, & the latest Aduhelm twist

Who’s going to run the FDA? Why isn’t the Biden administration leakier? And what if Aduhelm isn’t a blockbuster after all? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we’ll talk about the future of the FDA, whose acting commissioner will have to step down in November unless she’s given the permanent job. Next, Washington Post reporter Dan Diamond…

Aduhelm’s latest twist, how Covid variants are shaping the summer, & a digital health boom

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss the latest twists following the FDA’s widely condemned decision to approve Aduhelm, Biogen’s treatment for Alzheimer’s disease. Then, our STAT colleague Helen Branswell joins us to talk about whether viral variants are going to stymie the U.S.’s summer reopening. Finally, STAT’s Mario Aguilar…

A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021

How much can CRISPR really do? Has the FDA been totally honest? And is it OK to mix and match Covid-19 vaccines? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First we talk to George Yancopoulos, head scientist at Regeneron Pharmaceuticals, about the future of CRISPR genome editing and the latest idea for treating obesity. Then, we discuss STAT’s reporting on…

FDA inner workings, GSK’s foggy future, & the alarming rise in colorectal cancer

How does the FDA handle unprecedented decisions? What’s it like to go on “Good Morning America”? And does the world need a “New” GlaxoSmithKline? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we sift through the week’s news, with a major update from Eli Lilly in Alzheimer’s disease and new details on the inner workings of the FDA. Then, STAT’s Matthew…

The Covid vaccine booster debate, 23andMe hits Wall Street, & biotech’s call of the decade

Is 23andMe a tech company? Do we really need booster shots of Covid-19 vaccines? And what happens when mRNA goes wrong? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we sift through the week’s news, with some disappointing Covid-19 vaccine data, a pair of setbacks for biotech, and the Wall Street debut of 23andMe. Then, vaccinologist Paul Offit joins…

Every angle on the FDA’s polarizing approval of Biogen’s Alzheimer’s drug

Was the FDA right to approve Aduhelm? What’s a fair price for a debatable drug? And what does this have to do with ’80s HIV activism? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We’re devoting this entire episode to the FDA’s polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer’s disease. First, we’ll break down what…

Fauci’s emails, FDA kremlinology, & covering the CRISPR babies scandal

Who is Anthony Fauci emailing at 3 a.m.? Does the FDA leave legible tea leaves? And what’s it like to cover an international science scandal? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss why it’s so hard to predict FDA decisions, and why the latest big deal in biotech left investors cold. Then, STAT Washington correspondent Nicholas Florko…

Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA

What does “one-and-done” treatment actually mean? Do we really need a permanent FDA commissioner? And what’s Scott Gottlieb’s grilling technique? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Andrew Joseph joins us to talk about the two-year anniversary of the approval of gene therapy Zolgensma and the effect it has had on families dealing with…